CL2015002720A1 - Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc. - Google Patents

Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc.

Info

Publication number
CL2015002720A1
CL2015002720A1 CL2015002720A CL2015002720A CL2015002720A1 CL 2015002720 A1 CL2015002720 A1 CL 2015002720A1 CL 2015002720 A CL2015002720 A CL 2015002720A CL 2015002720 A CL2015002720 A CL 2015002720A CL 2015002720 A1 CL2015002720 A1 CL 2015002720A1
Authority
CL
Chile
Prior art keywords
composition
factor viii
chimeric polypeptide
fviii
pharmaceutical kit
Prior art date
Application number
CL2015002720A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Maloney
Ahmad Abdul-Fattah
Daniel Gage
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002720(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of CL2015002720A1 publication Critical patent/CL2015002720A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2015002720A 2013-03-15 2015-09-15 Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc. CL2015002720A1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30

Publications (1)

Publication Number Publication Date
CL2015002720A1 true CL2015002720A1 (es) 2016-11-04

Family

ID=50771579

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002720A CL2015002720A1 (es) 2013-03-15 2015-09-15 Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc.

Country Status (20)

Country Link
US (3) US9623088B2 (https=)
EP (3) EP4122487A1 (https=)
JP (5) JP6330026B2 (https=)
AU (4) AU2014228506A1 (https=)
CA (1) CA2899737A1 (https=)
CL (1) CL2015002720A1 (https=)
DK (1) DK2968477T3 (https=)
EA (2) EA201890671A1 (https=)
ES (2) ES2776195T3 (https=)
HU (1) HUE047933T2 (https=)
LT (1) LT2968477T (https=)
PH (2) PH12015501801B1 (https=)
PL (2) PL3666283T3 (https=)
PT (2) PT2968477T (https=)
RS (1) RS60003B1 (https=)
SG (2) SG10201805207QA (https=)
SI (1) SI2968477T1 (https=)
TW (2) TWI629993B (https=)
UY (1) UY35462A (https=)
WO (1) WO2014144795A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2506868T1 (en) * 2009-12-06 2018-04-30 Bioverativ Therapeutics Inc. HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
JP7039308B2 (ja) * 2017-02-08 2022-03-22 三洋化成工業株式会社 細胞培養用担体
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
JP7370974B2 (ja) 2017-11-07 2023-10-30 ラニ セラピューティクス， エルエルシー 嚥下可能薬物送達デバイスを使用する腸管組織への送達のための凝固因子調製物
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
JP7672334B2 (ja) * 2018-10-23 2025-05-07 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｖｉｉｉ因子機能を調節するための組成物および方法
WO2020175594A1 (ja) * 2019-02-28 2020-09-03 公立大学法人横浜市立大学 血液凝固および／または補体異常疾患の治療用組成物
SG11202111290WA (en) 2019-04-17 2021-11-29 Codiak Biosciences Inc Compositions of exosomes and aav
CN114007637A (zh) 2019-06-19 2022-02-01 比奥维拉迪维治疗股份有限公司 用于治疗血友病和低骨矿物质密度的重组因子viii-fc
WO2023219378A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질에 대한 신규한 액상 제형물
TW202400224A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 用於冷凍乾燥血漿蛋白之新穎液體調配物

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JP3045539B2 (ja) 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
DK1820516T3 (da) * 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
PT2363414T (pt) 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
CA2638811A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
ES2427627T3 (es) * 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas
SI2506868T1 (en) * 2009-12-06 2018-04-30 Bioverativ Therapeutics Inc. HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
PT3513804T (pt) * 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
KR20140084208A (ko) * 2011-10-18 2014-07-04 시에스엘 리미티드 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법
US20160000884A1 (en) 2012-08-13 2016-01-07 Novo Nordisk A/S Liquid Factor VIII Formulations
HK1214539A1 (zh) * 2012-10-30 2016-07-29 Bioverativ Therapeutics Inc. 應用viii因子多肽的方法
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations

Also Published As

Publication number Publication date
AU2025204069A1 (en) 2025-06-26
US20210069300A1 (en) 2021-03-11
TWI629993B (zh) 2018-07-21
RS60003B1 (sr) 2020-04-30
JP2018123161A (ja) 2018-08-09
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
PH12019502452A1 (en) 2021-02-08
PT2968477T (pt) 2020-03-11
TW201842930A (zh) 2018-12-16
DK2968477T3 (da) 2020-03-09
EP3666283A1 (en) 2020-06-17
US12403183B2 (en) 2025-09-02
JP2016516722A (ja) 2016-06-09
EP3666283B1 (en) 2022-06-08
EA030357B1 (ru) 2018-07-31
EP4122487A1 (en) 2023-01-25
AU2021277601A1 (en) 2021-12-23
ES2926798T3 (es) 2022-10-28
AU2021277601B2 (en) 2025-03-06
TW201501722A (zh) 2015-01-16
PL3666283T3 (pl) 2022-10-03
EA201591439A1 (ru) 2016-03-31
CA2899737A1 (en) 2014-09-18
EP2968477B1 (en) 2019-12-04
EA201890671A1 (ru) 2019-01-31
SG10201805207QA (en) 2018-07-30
SG11201505924TA (en) 2015-09-29
US20140308280A1 (en) 2014-10-16
TWI690325B (zh) 2020-04-11
JP7240457B2 (ja) 2023-03-15
ES2776195T3 (es) 2020-07-29
US9623088B2 (en) 2017-04-18
US10786554B2 (en) 2020-09-29
JP7700164B2 (ja) 2025-06-30
JP2020186268A (ja) 2020-11-19
HUE047933T2 (hu) 2020-05-28
EP2968477A1 (en) 2016-01-20
AU2025204069A9 (en) 2026-03-19
HK1220617A1 (en) 2017-05-12
PH12015501801B1 (en) 2019-11-20
JP6330026B2 (ja) 2018-05-23
LT2968477T (lt) 2020-03-10
JP2021181491A (ja) 2021-11-25
PL2968477T3 (pl) 2020-06-15
JP2023060146A (ja) 2023-04-27
JP6934994B2 (ja) 2021-09-15
UY35462A (es) 2014-10-31
PH12015501801A1 (en) 2015-11-09
WO2014144795A1 (en) 2014-09-18
PT3666283T (pt) 2022-09-13
SI2968477T1 (sl) 2020-04-30
US20170281734A1 (en) 2017-10-05
AU2014228506A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
CL2015002720A1 (es) Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc.
AR099079A1 (es) Variantes de región fc con propiedades de unión de fcrn modificadas
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CL2015000060A1 (es) Proteína quimérica que comrpende una proteína del factor von willebrand (vwf), una secuencia xten y una proteina del factor viii; polinucleótido que la codifica; vector; célula huésped; y composición farmacéutica útil en el tratamiento de la hemofilia.
CY1121953T1 (el) Κυτταροδιεισδυτικα πεπτιδια και μεθοδοι παρασκευης και χρησης αυτων
UY40420A (es) Formulación que comprende una superóxido dismutasa
GEAP202114720A (en) Constructs having a sirp-alpha domain or variant thereof
EP3704219C0 (en) POLYPEPTIDES AND COMPOSITIONS COMPRISING SUCH POLYPEPTIDES
TW201613958A (en) MIC-1 fusion proteins and uses thereof
CY1124911T1 (el) Συνθεσεις πεπτιδιων και μεθοδοι χρησης
MX2016014187A (es) Adenovirus que comprende una fraccion de union a albumina.
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
MX2016008782A (es) Variantes de region fc con union mejorada de la proteina a.
CR20160049A (es) Bioconjugados de polipéptidos de apelina sintética
PE20170471A1 (es) Polipeptidos receptores formulados y metodos relacionados
BR112017021706A2 (pt) recipientes flexíveis com visibilidade de dispensação do produto
WO2015061416A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
MX2017007458A (es) Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
MX2016008539A (es) Variantes de region fc con propiedades de union a receptor fc neonatal (fcrn) modificadas y de union a proteina a mantenidas.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
IL280678A (en) Cell-penetrating peptides
BR112017006112A2 (pt) formulação de proteína de fusão recombinante
AR095527A1 (es) Formulaciones de polipéptido fc-factor ix
UY35397A (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7